Alpha Tau to Participate in May Investor Conferences

Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT for treating solid tumors [2] - The technology behind Alpha DaRT was developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University [2] Product Information - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 impregnated sources [3] - The therapy aims to destroy tumors while sparing surrounding healthy tissue, as the alpha-emitting atoms diffuse only a short distance [3] Investor Engagement - CFO Raphi Levy will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, in New York, NY [1] - Additionally, Mr. Levy will participate in 1x1 meetings at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025, which will be held virtually [1]